Purpose: This study compared the heart rate (HR), rate of perceived exertion (RPE), and blood lactate (BL) responses to aerobic exercise between posttreated breast cancer patients and apparently healthy, age-matched controls. Methods: Seven patients and 7 control subjects underwent a submaximal treadmill test for the estimation of Vo 2max . Exercise intensities of 40%, 60%, and 70% of Vo 2max were calculated from the treadmill test and randomly examined between groups during three 9-minute exercise bouts on 3 different days. Independent samples t tests were used to examine the HR, RPE, and BL responses at each intensity between groups. Results: No significant differences were observed between the control and patient groups for HR, RPE, and BL at 40% (101 ± 9 vs 101 ± 11 bpm, P = .979; 8 ± 1 vs 9 ± 3, P = .237; and 1.11 ± 0.73 vs 1.26 ± 0.64 mmol/L, P = .188, respectively) and 60% (127 ± 17 vs 117 ± 13 bpm, P = .523; 12 ± 2 vs 11 ± 3, P = .267, and 3.83 ± 2.48 vs 2.23 ± 1.65 mmol/L, P = .237, respectively) of Vo 2max . At 70% of Vo 2max , no significant differences were found for HR (151 ± 27 vs 135 ± 13 bpm, P = .704) and RPE (14 ± 1 vs 13 ± 3, P = .181), but lower BL responses were observed in the patient group (7.70 ± 1.62 vs 3.29 ± 1.08 mmol/L, P < .0005). Conclusions: The results suggest similar HR, RPE, and BL responses between patients and control subjects at 40%, 60%, and 70% of Vo 2max , except for BL at 70% of Vo 2max . The lower BL response in the patient group at 70% of Vo 2max was somewhat unexpected. Further research is needed to confirm or refute the results of this study to allow for a clearer understanding of the physiological responses of breast cancer patients to aerobic exercise at moderate or higher intensities so that safer aerobic exercise prescriptions can be developed for this population.
physical distress experienced by breast cancer patients, affecting up to 70% of patients during therapy and up to 30% of patients years after the completion of therapy. 2 This type of fatigue is often severe and may limit activities of daily living; therefore, many patients are advised to rest and reduce their level of daily activities. 2 However, inactivity can lead to muscular atrophy, and prolonged rest can actually worsen fatigue, thus contributing to a cycle of further decline in physical performance and a consequent downregulation of daily activity levels. [2] [3] [4] Aerobic exercise has been shown to improve physical performance in breast cancer patients. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Significant increases in cardiovascular endurance and aerobic capacity, decreases in fatigue, and some improvements in blood parameters and immune function have been found. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Previous studies have described aerobic exercise intervention programs ranging in intensities of 50% to 85% of maximal (peak) oxygen uptake (Vo 2peak ), maximum heart rate, or heart rate reserve; frequencies of 3 to 5 days per week; and the duration of the training programs ranging from 8 to 26 weeks. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] These choices for aerobic exercise B reast cancer is the most common cancer in women and the second leading cause of cancer deaths in women in the United States. 1 Treatment for breast cancer, including surgery, chemotherapy, and radiation therapy, can cause significant physical and psychological distress that may persist for months or years after the completion of therapy. 1 Fatigue is the most common intervention parameters, particularly intensity, are modeled after the current guidelines employed for cardiac patients or sedentary adults. In 2 recent reviews, Ko and McKelvie 14 and Smart et al 15 reported that most studies examining the effects of aerobic training on patients with heart failure have used intensities of 40% to 80% Vo 2peak . Additionally, many studies involving cardiac patients have also used heart rate (HR) and Borg's rating of perceived exertion (RPE) as guidelines for aerobic exercise intensity. Intensities ranging from 50% to 80% of HR reserve, 60% to 85% of predetermined peak HR, 40% to 65% of maximal HR, and RPE ratings of 12 to 14 have successfully been used to study the effects of aerobic exercise on patients with heart failure. [14] [15] [16] [17] [18] [19] [20] Other studies examining the effect of exercise on cardiac patients have also used blood lactate concentration and lactate threshold to describe exercise intensity. 21, 22 In the cardiac patient population, it is thought that lower intensities of 40% to 50% Vo 2max may be more advantageous than higher intensities of 70% to 80% Vo 2max because the former may reduce the risk of left ventricular dilation, minimizing stress on the left ventricular wall. 17 However, it is not yet known whether similar exercise intensities currently prescribed for breast cancer patients are the most appropriate for eliciting the desired physiological changes without compromising other physiological functions. Furthermore, it is not yet known whether the currently prescribed exercise intensity levels are even an accurate or consistent measure of a cancer patient's true level of exertion. What is needed are models that describe physiological responses to differing levels of aerobic exercise for cancer patients compared with healthy controls, so that it may be determined whether the currently prescribed exercise intensities are an accurate measure of a patient's true level of exertion, relative to their normal healthy counterparts. The purpose of this study was to compare the response to low-, moderate-, and high-intensity aerobic exercise in posttreated breast cancer patients and healthy controls, using 3 indicators of exercise intensity: HR, RPE, and postexercise blood lactate (BL).
Methods

Subjects
This study included 14 women separated into 2 groups: a patient group consisting of women who were posttreated breast cancer patients (n = 7) and a control group consisting of apparently healthy age-matched women (n = 7). Subjects in the patient group were breast cancer patients who were within 6 months of completion of all major cancer therapy and were newly enrolled in the Get REAL & HEEL Breast Cancer Program at the University of North Carolina at Chapel Hill (UNC-Chapel Hill).
Subjects in the control group were women recruited from the faculty, staff, and student populations at UNC-Chapel Hill; had not been enrolled in regular organized physical activity during the past 3 months; and were healthy enough to participate in aerobic exercise. All attempts were made to match subjects in both groups based on age and physical activity level. The criteria for participation in the study for the patient group included the following: confirmed diagnosis of stage I, II, or III invasive breast cancer; within 6 months of completion of all major cancer treatment; ages ranging from 30 to 75 years; no presence of metastatic disease; and no presence of immune deficiency that would compromise the subject's ability to participate in regular exercise. Patients receiving adjuvant hormonal therapy or adjuvant trastuzumab were also eligible to participate in the study.
Participation in this study involved the same risks as any exercise regimen. Each subject in both groups was informed about the possible risks and benefits of participating in the study and signed a consent form approved by the UNC-Chapel Hill Biomedical Institutional Review Board, as well as the HIPAA authorization for use and disclosure of health information for research purposes form prior to starting in the study. Given the potential risks involved, all subjects completed a comprehensive medical history questionnaire and were screened for exclusion based on the following criteria: presence of cardiovascular disease, acute or chronic respiratory disease, and/or acute or chronic bone, joint, or muscular abnormalities (unless the disease or abnormality would not compromise the subject's ability to participate in the exercise rehabilitation program). In the patient group, 5 of the 7 subjects received anthracycline-based chemotherapy, and 2 of the 7 subjects received adjuvant trastuzumab therapy, which could have potentially put them at risk for cardiotoxicity. To that end, multigated acquisition scans were performed on all subjects in the patient group prior to enrollment, and there were no incidences of chemotherapy-induced or trastuzumab-induced heart failure or left ventricular ejection fraction abnormalities that would preclude subjects from participating in regular exercise.
Demographic Parameters
Age, race, menopausal status, height, weight, percentage body fat, and current physical activity level were recorded for all subjects on enrollment in the study. Height and weight were used to calculate body mass index. Menopausal status was assessed by asking subjects if they would classify themselves as premenopausal, perimenopausal, or postmenopausal. For subjects in the patient group, menopausal status before beginning major cancer treatment was recorded. Percentage body fat was estimated using the Pollock 3-site (triceps, suprailiac, and abdomen) skinfold measurement formula for women using a Lange C-130 Beta Technology calipers (Cambridge, MD). 23 Current physical activity was assessed using the International Physical Activity Questionnaire. 24 For the subjects in the patient group, breast cancer stage and type of treatment received was also recorded.
Procedure
Each subject participated in a total of 4 sessions, including an initial assessment and 3 aerobic exercise trials, 1 at each prescribed aerobic intensity (40%, 60%, and 70% of Vo 2max ). All subjects were asked to follow a set of preassessment guidelines before each session that included no eating for at least 2 hours prior to testing, no exercise for at least 12 hours prior to testing, to maintain adequate hydration, to refrain from caffeine use for at least 12 hours prior to testing, to refrain from alcohol use for at least 48 hours prior to testing, and to refrain from using diuretic medications for at least 7 days prior to testing.
The testing sessions were performed at the Get REAL & HEEL Breast Cancer Program facilities, located in the Department of Exercise and Sport Science at UNC-Chapel Hill. For each subject, the period of time from the initial assessment to the final exercise trial was approximately 1 to 2 weeks.
Initial Assessment
As soon subjects reported to the Get REAL & HEEL Breast Cancer Program facilities, they were asked to remain seated quietly for 5 minutes at which time resting vitals (resting heart rate assessed via a Pacer Polar heart rate monitor [Lake Success, NY], blood pressure via a Diagnostix 700 aneroid sphygmomanometer [Hauppauge, NY], and a Litmann stethoscope [St Paul, MN]) were assessed. Height and weight were obtained following the assessment of resting vitals using a balance beam physician scale equipped with a height rod (Health-o-meter 402KL; Rye, NY). The Modified Bruce Submaximal Treadmill Protocol was used to predict Vo 2max for each subject and was performed on a treadmill model Quinton Q65 (Fitness Equipment, Bothell, WA). This was a multistage protocol, where each stage lasted 3 minutes in duration with incremental increases in both treadmill speed and grade. The assessment was terminated when a subject's HR reaches a target HR of 75% of heart rate reserve (HRR), calculated using the Karvonen formula. HR and RPE were recorded at the end of each stage. Borg's Rating of Perceived Exertion Scale (6-20 point scale) was used to quantify RPE. 25 Vo 2max was estimated for each subject, using the following prediction equation 26 : Vo 2max = 2.282 * (time) + 8.545. This equation accounts for the use of handrails during the test, which was adopted as safety measure, and because a pilot study indicated that patients needed to hold the handrails primarily during the 70% of Vo 2max . After estimating Vo 2max for each subject, the training intensities of 40%, 60%, and 70% of Vo 2max were calculated for each subject. To calculate the treadmill speed and grade that corresponded to 40%, 60%, and 70% of Vo 2max , the horizontal and vertical components of Vo 2 were given equal weights of 50% and 50%, respectively.
Aerobic Exercise Trials
Each trial consisted of a warm-up/stretch period, an exercise trial, and a cool-down period. The warm-up/stretch period was approximately 10 minutes in duration and was standard for all subjects. Each subject walked on the treadmill for 5 minutes at 1.7 miles per hour at 0% grade, which generally corresponded to an RPE of 6 to 7 (ie, "no exertion" to "extremely light"). Then, the treadmill was stopped so that the subjects could step off and stretch for approximately 5 minutes, targeting particularly the muscles of the hips and legs.
After the subjects had properly stretched, they stepped back on the treadmill to start the exercise trial. The exercise trials were each 9 minutes in duration and were performed at the prescribed intensity for the day. The trials were randomized to prevent an order effect and were blinded to the subjects.
A duration of 9 minutes had been chosen a priori based on a pilot test performed on several patients who had been currently participating in the Get REAL & HEEL Breast Cancer Program, who felt that this was long enough for them to be able to complete an exercise trial at any intensity including the high intensity (70% of Vo 2max ) trial. Once the treadmill speed and grade were set, a stopwatch (Accusplit Pro Survivor, Pleasanton, CA) was used to monitor time. HR and RPE were recorded minute by minute during the sessions (ie, between 1:50 and 2:00, between 2:50 and 3:00, between 3:50 and 4:00, etc.).
After the conclusion of each trial, subjects were asked to sit in a chair for 3 minutes so that a finger prick blood sample could be collected for the analyses of postexercise BL. BL was analyzed using a Lactate Plus blood lactate analyzer (Sports Resource Group, Inc, Hawthorne, NY).
Statistical Analysis
Data for the HR, RPE, and postexercise BL responses for the control group and the patient group were averaged for each of the 9-minute exercise trials. Analysis of the HR, RPE, and postexercise BL responses between the groups was performed using independent samples t tests. All data were analyzed on SPSS version 15.0 for Windows. An α level of .05 was used for all analyses.
Results
Subjects
All subjects in the patients group had undergone surgery, chemotherapy, and radiation therapy as part of their treatment for breast cancer. At the time of the study, 4 subjects in the patient group were receiving additional adjuvant therapies that included Herceptin, Femara, or Tamoxifen. Three subjects in the patient group had been diagnosed with stage II breast cancer, and 4 subjects had been diagnosed with stage III breast cancer. Subject characteristics are presented in Table 1 . Descriptive statistics are presented in the form of mean ± standard deviation. Comparisons between the control group and the experimental group were made using independent samples t tests, where appropriate.
Heart Rate Responses to the Aerobic Exercise Trials
The average HR responses to the 9-minute aerobic exercise trials at 40%, 60%, and 70% of Vo 2max are presented in Figure 1 . There were no statistically significant differences in the response between the control group and the patient group at either 40% (101 ± 9 vs 101 ± 11 bpm, P = .979), 60% (127 ± 17 vs 117 ± 13 bpm, P = .523), or 70% of Vo 2max (151 ± 27 vs 135 ± 13 bpm, P = .704).
RPE Responses to the Aerobic Exercise Trials
The average RPE responses to the 9-mintue aerobic exercise trials at 40%, 60%, and 70% of Vo 2max are presented in Figure 2 . There were no statistically significant differences in the response between the control group and the patient group at either 40% (8 ± 1 vs 9 ± 3, P = .237), 60% (12 ± 2 vs 11 ± 3, P = .267), or 70% of Vo 2max (14 ± 1 vs 13 ± 3, P = .181).
Postexercise Blood Lactate Responses to the Aerobic Exercise Trials
The average postexercise BL responses to the aerobic exercise trials at 40%, 60%, and 70% of Vo 2max are presented in Figure 3 . There were no significant differences in the response between the control group and the patient group at either 40% (1.11 ± 0.73 vs 1.26 ± 0.64 mmol/L, P = .188) or 60% of Vo 2max (3.83 ± 2.48 vs 2.23 ± 1.65 mmol/L, P = .237). At 70% of Vo 2max , a significantly lower postexercise BL level was observed in the patient group (7.70 ± 1.62 vs 3.29 ± 1.08, P < .0005).
Discussion
The existing literature reporting the effects of aerobic exercise in the breast cancer patient population is encouraging, in that aerobic exercise of various intensities seems to elicit many positive adaptations in physiological and psychological parameters. When considering low-intensity aerobic exercise, Dimeo et al 3, 5 investigated the effects of physical exercise on physical performance, severity of treatment complications, and psychological distress in cancer patients, using an exercise intensity of 50% of HRR. In the first study, 70 patients (including 46 breast cancer patients) participated in an exercise sessions that included alternating bouts of 1 minute of cycling and 1 minute of rest, for a total of 30 minutes. In the second study, 59 patients (including 31 breast cancer patients) participated in an exercise program that included the same type of interval cycling. Both studies revealed positive results, including increased physical performance and decreased thrombopenia, neutropenia, psychological distress, and time spent in the hospital. In another study using low aerobic exercise intensity, Battaglini et al 27 examined a group of 27 patients including 22 breast cancer patients who participated in an exercise program where aerobic exercise intensity was set between 50% and 55% of maximal HR, which is similar to the low intensity used in the current study. Significant improvement in cardiorespiratory endurance of approximately 30% was observed with no adverse effects of the intensity used being reported. In a follow-up study, Battaglini et al 28 investigated the exercise response in a group of 20 breast cancer patients who were undergoing chemotherapy treatment. Patients assigned to the exercise group participated in a structured exercise program at intensities ranging between 40% and 60% of Vo 2max for a period of approximately 21 weeks. Again, no adverse effects to the intensities used in the second Battaglini et al 28 reported. Furthermore, significant decreases in fatigue were observed in the exercise group when compared with the control group at the end of the first, second, and final bout of chemotherapy treatment. Several studies have used intensities above 50% of Vo 2max to examine the impact of aerobic exercise on various endpoints in breast cancer patients. 1, 4, [7] [8] [9] 29 Segal et al 4 investigated the effect of a self-paced walking intervention along with a supervised exercise program at 50% to 60% of Vo 2max on health-related quality of life in 123 breast cancer patients during a 26-week period. In patients who did not receive chemotherapy, aerobic capacity was significant increased, whereas body weight was significantly decreased in patients participating in supervised exercise compared with patients receiving usual care. In a study using slightly higher exercise intensities than the previously cited studies, Kim et al 1 studied cardiopulmonary responses and adherence to exercise after an 8-week exercise intervention in 41 posttreated breast cancer patients. Patients participated in supervised aerobic exercise at an intensity of 60% to 70% Vo 2peak and/or HRR for 30 minutes per day, 3 days per week. The results showed that patients participating in exercise had decreased resting HR, resting systolic blood pressure, and an increased Vo 2peak .
study were
Using intensities slightly higher than those used by Kim et al 1 and Segal et al, 4 intensities varying from 60% to 80% of Vo 2max have also promoted positive physiological adaptations without adverse effects. In a series of 3 studies, Fairey et al [7] [8] [9] investigated the effect of exercise training on several blood markers and various cardiovascular disease risk factors using aerobic exercise with intensities within 70% to 75% of Vo 2max . Positive changes were observed for cardiovascular function and disease risk factors, including increased Vo 2max , decreased C-reactive protein, resting HR, blood pressure, and high-density lipoprotein cholesterol. An increase in NK cell activity was also observed, as well as changes in levels of insulinlike growth factors and insulin-like growth factor binding proteins. In a multicenter study conducted by Courneya et al, 29 78 breast cancer patients participated in a 12-week intervention, where aerobic exercise intensity progressed from 60% to 80% of Vo 2max . Increases in aerobic fitness, self-esteem, and improved body composition without significant adverse events were all observed.
According to the current literature, it appears that breast cancer patients are able to tolerate different exercise intensities, even those considered high for individuals with no history of cancer or any other comorbidity. Furthermore, positive changes in various physiological and psychological parameters have also been successfully reported. Even though well-conducted experiments have presented promising results by using various aerobic exercise intensities with breast cancer patients (most of whom have completed their major cancer treatments), we still need to examine the impact of these intensities on long-term physiological function and overall health. The lack of sufficient information necessary for the determination of precise exercise prescriptions in the cancer patient population is of concern. Studies addressing basic physiological mechanisms of response to different exercise intensities in this population are needed.
The current study compares the cardiovascular and BL responses to different intensities of aerobic exercise performed on a treadmill between a group of posttreated breast cancer patients and apparently healthy women with similar age and cardiorespiratory fitness level. The goal of this study was to examine if cardiovascular and BL responses between patients and apparently healthy women were in fact similar, in order to confirm that current research practices are using appropriate exercise intensity protocols. This study is one of the first studies that attempted to examine how posttreated breast cancer patients respond to acute bouts of low-, moderate-, and high-intensity aerobic exercise. The results of the current study suggest that the patient group responded similarly to the control group with respect to HR, RPE, at low-, moderate-, and high-intensity aerobic exercise, as well as postexercise BL at low and moderate aerobic exercise intensities. This confirms that the currently aerobic exercise recommendations are appropriate. 30 The results of this study may also be used as the initial step for the creation of a basic body of knowledge necessary for the development of future aerobic exercise guidelines specifically designed for the breast cancer population. 30 However, it is important to note that even though HR and RPE were similar between the patient and control groups for all intensities examined, postexercise BL response was significantly lower in the patient group at 70% of Vo 2max . Because high-intensity aerobic exercise with intensities at or above 70% of Vo 2max should not be prescribed at the beginning of an exercise program to any population that has a low cardiorespiratory fitness level, the lower BL concentration observed in the patient group when compared with the control group was unexpected. A few possible reasons for the difference in BL concentrations between the patient and control groups at 70% of Vo 2max may be explained by factors including the difference in the mean age of the groups and the protocol used during the initial assessment for the determination of Vo 2max . Even though no significant difference was observed in age between groups, the patient group was older than the control group by approximately 8 years, which may be of clinical relevance. For example, muscle biochemistry changes with age, including decreases in glycolytic enzymes. 31 This includes the enzyme lactate dehydrogenase, which is responsible for the production of lactic acid, especially during more intense exercise. 31 Because the patient group was older than the control group, this may help explain the differences in postexercise BL response at 70% of Vo 2max . Additionally, differences in menopausal status may have contributed to the significant differences in BL between the groups. High levels of estrogen decreases carbohydrate metabolism and increases lipid metabolism; therefore, women who are in the luteal phase of the menstrual cycle experience decreased glucose oxidation and consequently lower lactate production during exercise. 32, 33 On the other hand, women who are experiencing oligomenorrhea or amenorrhea because of the onset of menopause have decreased levels of estrogen and, therefore, increased carbohydrate metabolism and lactate production during exercise. 32, 33 It is possible that the differences in menopausal status between subjects, as well as menstrual cycle phase, may have also contributed to the postexercise BL results of the 2 study groups in response to the exercise trial at 70% of Vo 2max .
The protocol during the initial assessment to predict Vo 2max , as well as the method used to calculate predicted Vo 2max , may have also contributed to the significant difference in postexercise BL between the groups. The Modified Bruce Protocol, a submaximal cardiorespiratory test, was chosen for this study because it is recommended for use in high-risk cardiac patient and elderly adult populations; therefore, it should be a suitable protocol to use with posttreated breast cancer patients. 26 Even though the submaximal test allowed for the estimation of Vo 2max , it is just an estimation and it is not as precise as determining Vo 2max from a maximal test. Some recent evidence has shown that when properly supervised a maximal test can be safely used in the cancer population. 34 Therefore, the use of maximal protocol should be implemented in future studies attempting to verify the cardiovascular responses between posttreated breast cancer patients and apparently healthy control subjects.
Recommendations for Future Studies
The basis for the current study is the need to start investigating the basic physiological responses to exercise in the breast cancer population. Even though the literature on the use of exercise in the cancer population has shown promising improvements in many physiological systems, there is very little evidence-based information on basic physiological responses of breast cancer patients to different exercise intensities. By creating evidence-based knowledge on the basic physiological responses of breast cancer patients during exercise, safer and more efficacious exercise prescriptions can be more confidently developed, implemented, and supported by the medical community. Therefore, future experiments should consider the following recommendations.
First, a larger sample size of patients and controls should be obtained so that the impact of aerobic exercise intensity can be evaluated in a greater number of individuals. Second, subjects in the experimental and control groups should be age-matched more closely. Additionally, a smaller age range should be used (ie, 40-50 years of age rather than 30-75 years of age), which may help minimize the effect of age differences on cardiovascular responses and lactate production during exercise. Third, a more accurate assessment of menopausal status should be considered, because estrogen levels can affect the carbohydrate metabolism and the production of lactate during exercise. Similarly, menstrual cycle phase should be controlled for more closely when scheduling the exercise trials.
When considering subject recruitment, for a more homogeneous sample of posttreated breast cancer patients, a shorter posttreatment window should be considered to more closely control for the type and severity of side effects experienced by the experimental group, which may affect performance during the initial assessment and exercise trials. Also, a window of physical inactivity of at least 1 year should be considered when recruiting control subjects. This should be done to make more precise comparisons between individuals with more closely matched aerobic fitness levels.
Once studies have been conducted that help clarify the impact of aerobic exercise intensity on posttreated breast cancer patients, studies using patients who are undergoing treatment should also be considered. Additionally, studies exploring the impact of exercise intensity on immune function in breast cancer patients compared with healthy controls and the cumulative effect of chronic exercise training on physiological functioning in breast cancer patients should be considered.
Conclusion
Low-, moderate-, and high-intensity aerobic exercise does not seem to elicit significant differences in HR or RPE response in posttreated breast cancer patients compared with healthy controls. Likewise, low-and moderate-intensity aerobic exercise does not seem to elicit significant differences in postexercise BL response; however, at high aerobic exercise intensities, the postexercise BL response must be explored further. Factors such as small sample size and mean age difference between the 2 groups may have contributed to the differing BL responses seen in this study. According to current literature involving the use of exercise in the breast cancer population, no evidence of contraindication for high-intensity exercise has been confirmed; but basic science is needed to confidently confirm or refute the current findings and to allow for the development of more specific exercise guidelines for the breast cancer population.
